Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Paxalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 122,115Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia Therapeutics Hits Initial iCR in Metastatic TNBC
    Kazia Therapeutics Hits Initial iCR in Metastatic TNBC

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share
    Kazia’s Paxalisib Combo Shows 86% Tumor Drop in Metastatic TNBC
    Kazia’s Paxalisib Combo Shows 86% Tumor Drop in Metastatic TNBC

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-86-reduction-in-tumor-burden-in-expanded-access-case-of-metastatic-tnbc-patient-treated-with-paxalisib-immunotherapy-regimen-302573460.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Kazia Paxalisib Disrupts Stage IV Breast Cancer Cells
    Kazia Paxalisib Disrupts Stage IV Breast Cancer Cells

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-complete-ex-vivo-disruption-of-large-circulating-tumor-cell-clusters-in-stage-iv-her2-positive-breast-cancer-with-paxalisib-monotherapy-302553345.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Kazia Sees >50% Tumor Drop In Paxalisib Combo Trial
    Kazia Sees >50% Tumor Drop In Paxalisib Combo Trial

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-early-efficacy-data-from-first-triple-negative-breast-cancer-patient-receiving-paxalisib-combination-regimen-achieving-50-reduction-in-circulating-tumor-cells-in-phase-1b-trial-302500778.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    Kazia Therapeutics Updates on Recent Progress and Business
    Kazia Therapeutics Updates on Recent Progress and Business

    15 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-highlights-recent-progress-and-provides-business-update-302456503.html

    PR NEWSWIRE
    15 May 2025
    Share Share
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer

    30 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combination-with-immunotherapy-in-women-with-advanced-breast-cancer-302364230.html

    PR NEWSWIRE
    30 Jan 2025
    Share Share